Quality of
Pharmaceutical Veterinary Medicines

Presented by: Teresa Potter, European Medicines Agency
Quality of Pharmaceutical Veterinary Medicines

Scope of this presentation does not cover:

• Immunologicals / vaccines (*previous session*)
• Herbals
• Medicated feedingstuffs (only premixes – used for the production of medicated feeds)
• Homeopathics
• Good Manufacturing Practice (GMP) / Quality Defects / Rapid Alerts / falsified products / other Inspections issues (*see “Common Session on Inspections”*)
• Format issues = Human Common Technical Document (CTD) versus Veterinary Notice To Applicants (NTA)
Quality of EU Veterinary Medicines

Quality requirements for EU marketing authorisations for pharmaceutical veterinary medicinal products

Differences in EU Quality data requirements for veterinary and human medicinal products

EU Quality guidance and where to find it

Joint CHMP/CVMP Quality Working Party

Some current Quality issues

Any questions?
Legal background to quality requirements

(See volume 5 of EU pharmaceutical legislation - Eudralex)

Annex I of Directive 2009/9/EC:
Requirements for Veterinary Medicinal Products

Monographs of the European Pharmacopoeia (Ph.Eur.) Specific active ingredients, dosage forms (& vaccines)

(Rarely....) Individual Member States restrictions
e.g., (vaccines) “unknown disease” on their territory, premixes...
EU Marketing Authorisation applications

Part 1 Application form, expert reports and product literature, benefit-risk report

Part 2 Quality (chemistry and pharmacy)

Part 3 Safety (pharm-tox., environment, operator, consumer)

Part 4 Efficacy (preclinical and clinical)
Part 2 Quality (chemistry and pharmacy) - 1

A. QUALITATIVE AND QUANTITATIVE PARTICULARS OF THE CONSTITUENTS

1. Qualitative particulars
2. Usual terminology
3. Quantitative particulars
4. Development pharmaceutics

B. DESCRIPTION OF THE MANUFACTURING METHOD

C. CONTROL OF STARTING MATERIALS

1. General requirements
1.1. Active Substances
1.1.1. Active substances listed in pharmacopoeias
1.1.2. Active substances not in a pharmacopoeia
1.1.3. Physico-chemical characteristics liable to affect bioavailability
1.2. Excipients

6 Quality of pharmaceutical veterinary medicines
C. CONTROL OF STARTING MATERIALS - continued

1.3. Container-closure systems

1.3.1. Active substance

1.3.2. Finished Product

1.4. Substances of biological origin

D. CONTROL TESTS CARRIED OUT AT INTERMEDIATE STAGES OF THE MANUFACTURING PROCESS

E. TESTS ON THE FINISHED PRODUCT

1. General characteristics of the finished product

2. Identification and assay of active substance(s)

3. Identification and assay of excipient components

4. Safety tests

F. STABILITY TEST

1. Active substances(s)

2. Finished product

G. OTHER INFORMATION
Differences in EU Quality requirements for Veterinary and Human medicinal products

In principal the same data requirements, with the exception of:

• Herbal medicinal products (Directive 2004/24/EC for traditional herbal medicinal products – but only for Human use)

• Medical Devices (Directive only for Human Devices)

• No Radiopharmaceuticals authorised for Veterinary use

• Veterinary specific pharmaceutical forms (premixes for medicated feedingstuffs, intramammaries, pour-on products, spot-on products, products for administration via drinking water, bee-hive products, etc)
EU guidance on Quality

European Pharmacopoeia (Ph.Eur.) - mandatory and non-mandatory monographs

*Prepared by the relevant CxMP Working Party; detailed guidance for authorisation procedures:*

Guidelines (GLs) (CxMP) - each preceded by a Concept Paper; *draft* GLs published for public consultation; final adopted GLs (with an implementation date)

Guidelines (VICH) - once finalised are adopted as EU GLs

Question & Answer documents – published EEA harmonised position on issues open to differing interpretations and/or needing clarification, e.g., issues on borderline between Inspections (e.g., GMP) and quality requirements
VICH Guidelines

International Cooperation on Harmonization of Technical Requirements for Registration of Veterinary Medicinal Products  http://www.vichsec.org/

Members = EU, USA, Japan

Observers = Canada, NZ, Australia

Global Outreach Strategy
Where is the EU Quality guidance?

Guidelines (EU & VICH, draft & adopted), Concept Papers, Questions & Answer documents

EMA Veterinary Medicines website:

Question & Answer documents:

EMA Inspections website:

Quality of pharmaceutical veterinary medicines
Where is this EU Quality guidance?

(Other)

“Minor markets” (= minor uses / minor species)


Multidisciplinary (chiral active substances)

Joint CHMP/CVMP Quality Working Party

Joint Human and Veterinary Working Party – the only one!

• Chairman (Dr Jean-Louis Robert, LUX)
• 2 Vice Chairpersons - Human (Mrs Diana Van Riet-Nales, NL) & Veterinary (Dr Piet-Hein Overhaus, NL)
• 50+ Members = 1 Human + 1 Vet. representative (unless joint agency) from each EU + EEA Member State (Norway & Iceland)
• Observers = EU pre-accession countries, European Commission, EDQM (European Directorate for Quality of Medicines, Strasbourg, FR) & sometimes from Regulatory Authorities outside EU, especially MRA partners (Canada, US, Switzerland, Thailand)
• Meets 4 times a year (each time 2.5 to 3 days) at EMA
• Meets once a year with industry (associations)

13 Quality of pharmaceutical veterinary medicines
QWP - Mandate

Mandate = harmonisation of Quality issues in EU by....

• development of Guidelines (CHMP/CVMP & ICH/VICH)
• discussions on practical implementation of Guidelines
• Scientific Advice (Quality aspects) for applications
• product related issues
• interaction with other groups (European Commission, EDQM including Ph.Eur., Official Medicines Control Laboratories) and Working Parties (Ad Hoc GMDP Inspection Working Group, Safety Working Party, etc)
• dialogue with other Committees (e.g., HMPC, Paediatrics), interested parties, etc
QWP – Work Programme

Published each year, what the QWP plans to work on, how many meetings, etc........

For 2011:

Some topical Quality issues

Process Analytical Technologies (PAT)

New technologies/approaches in (Human) ICH Guidelines Q8 (Pharmaceutical Development), Q9 (Quality Risk Management) and Q10 (Pharmaceutical Quality Systems)

Bioequivalence guidance - revision of EU guideline and work on draft new VICH Bioequivalence guidance

Generics

Setting specifications for related substances in antibiotics

Use of Near Infra Red Spectroscopy
Contact point for questions

Queries relating to general Quality issues, published documents, QWP, etc, can be sent to QWP@ema.europa.eu